Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Half price sale

Half price sale

posted on Mar 25, 2008 09:19AM

I’m still looking for a $1 + stock price before the Q report. It’s justified, even based on a business as usual outlook. After the Q report will be too late to get in on the current sale prices.

EPS per License for past 4 quarters = .00416

Licenses this Q times .004 = .067 EPS

Given .067 EPS this Q = .117 TTM EPS

SP Given .117 TTM EPS times PE of 10 = $1.17 SP

The $1.17 SP is based on business as usual, which it’s not.

Nothing is factored in for the expected higher per license sales prices.

Nothing is factored in for lower expenses per license attributed to this Q’s unprecedented 16 licenses, compared to 5 or less in the previous 4 Qs.

Nothing is factored in for the greatly improved outlook as a result of the litigation settlement.

Nothing is factored in for recognition that PTSC product is recession proof.

Nothing is factored in for the remarkably clean and transparent financials.

Nothing is factored in for the substantial, and growing, cash reserves.

Share
New Message
Please login to post a reply